Recently, Mylan Inc.‘s (MYL) subsidiary, Matrix Laboratories received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) capsules in two dosage forms (15 mg and 30 mg). Mylan plans to begin shipment of the product immediately.  The drug is the generic version of Takeda Pharmaceuticals' (TKPHY.PK) proton pump inhibitor Prevacid DR Capsules. According to IMS Health (RX), the branded version had US sales of approximately $3 billion for the 12 months ending June 30.  Mylan received quite a few approvals in the recent past. In October, Mylan settled its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole), following which Mylan received the approval to launch the generic version of the drug. Additionally, in September, Mylan received FDA approval for its generic version of Bristol-Myers Squibb's (BMY) Sinemet ...

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic competition, including Lipitor, Plavix and Seretide. At the same time, new products are not expected to generate the same level of sales as the products losing patent protection have. With most of the big pharma companies already facing patent challenges for their blockbuster products or likely to face them going forward, the companies have been looking toward mergers ...

For Immediate Release

Chicago, IL – October 30, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Bank of America (BAC), Citigroup (C), Motorola Inc. (MOT), China Mobile Ltd. (CHL) and Mylan, Inc. (MYL).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Thursday’s AnalystBlog:

Contributions to GDP Growth

While residential investment is still near a record low share of the overall economy, I have serious questions about the sustainability of the increase. The extension and expansion of the the tax credit by Congress might keep things going for the next few quarters, but

...

Mylan, Inc. (MYL) reported third quarter earnings per share of 32 cents, above both the Zacks Consensus Estimate of 27 cents and 23 cents in the prior-year period. The company reported revenues of $1.26 billion, a 24% decline from the year-ago period. However, the year-ago period included $455 million of revenue related to the sale of the product rights of Bystolic. Excluding this, total revenues increased 5.2% over the third quarter 2008. Revenues would have increased 9%, but for the unfavorable movement of foreign currency. From this quarter onwards, Mylan has decided to report its results in two segments -- Generics and Specialty -- following the acquisition of approximately 24% of the remaining interest in Matrix and the related de-listing. The former Matrix segment has been included in the Generics segment. The Generics Segment, accounting for about 88% of total revenues during the quarter, increased marginally ...

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Monday October 19, 2009

DrStockPick.com Stock Report!

AMLN, PWRM, MMM, CSRH, MYL, CVAT, STEM, AQNM

**************************************************************

AMLN, Amylin Pharmaceuticals, Inc.

AMLN is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

AMLN will webcast its Quarterly Update Conference Call for the third quarter of 2009 on Tuesday, October 20, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin’s president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the third quarter of 2009.

**************************************************************

PWRM, Power 3 Medical Products Inc, PWRM.OB

Power3 Medical Products, Inc. is a

...

Salix Pharmaceuticals (SLXP) is working on gaining approval from the U.S. Food and Drug Administration (FDA) for new indications of rifaximin, which should help in driving long-term growth. Rifaximin is currently marketed for the treatment of patients, aged 12 years or more, with travelers diarrhea caused by non-invasive strains of E coli.  Salix received a boost recently when it announced positive results from two pivotal phase III trials of rifaximin for the treatment of non-constipation irritable bowel syndrome (IBS). Two randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, were conducted to evaluate the efficacy and safety of rifaximin 550 mg. Patients treated with rifaximin saw statistically significant improvement in the primary endpoint compared with placebo. Rifaximin also achieved statistical significance in the key secondary endpoint of providing relief from IBS-related bloating.  Favorable data from these studies is a major positive for the company. Rifaximin ...

Shares of Salix Pharmaceuticals (SLXP) jumped 51% yesterday after the company announced positive results from two pivotal phase III trials of rifaximin for the treatment of non-constipation irritable bowel syndrome (IBS).

Two randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, were conducted to evaluate the efficacy and safety of rifaximin 550 mg. Patients treated with rifaximin saw statistically significant improvement in the primary endpoint compared with placebo. Rifaximin also achieved statistical significance in the key secondary endpoint of providing relief from IBS-related bloating.

Positive data from these studies is a major positive for the company. Rifaximin has become the company’s primary growth driver following the introduction of generic versions of Colazal in December 2007 by three players including Mylan Inc. (MYL).

Salix has been working on new indications of rifaximin, which should help in driving long-term growth. Rifaximin is currently marketed for the treatment of

...

 

PennyOmega.com Hot Stock News & Alerts!

________________________________________

FREE Daily Stock Alerts From PennyOmega.com

________________________________________

 

Wednesday September 2nd, 2009

PennyOmega.com Stock Report!

**************************************************************

Bristol-Myers Squibb Co. (NYSE: BMY) completed its $2.1 billion acquisition of Medarex Inc., a biotech drugmaker developing treatments for immune system diseases and cancer.

Mylan Inc. (Nasdaq: MYL) is selling version of Sepracor’s Xopenex with 180-day marketing exclusivity. According to IMS Health, sales of inhalable Xopenex were $18.3 million over

...

Merck (MRK) received a favorable ruling in a major patent-infringement suit yesterday against the largest generic player, Teva Pharmaceuticals (TEVA), on its top-selling drug Singulair. Teva was seeking the Food and Drug Administration’s (FDA) approval for selling a generic version of the drug for asthma and allergic rhinitis. The litigation has been continuing since Merck sued Teva in February 2007.

During the second quarter of 2009, Singulair recorded worldwide sales of $1.3 billion, up 16% from the year-ago period. The drug had total sales of $4.3 billion in fiscal 2008, accounting for about 18% of Merck’s total revenue. Defending Singulair’s patent was thus quite crucial for Merck.

We believe this is a major win for Merck as an unfavorable ruling would have hurt its top-line badly. The court not only upheld Merck's patent, but also issued an injunction blocking the approval of Teva's generics till Singulair’s patent

...

DrStockPick.com Stock Report!

Wednesday August 19, 2009

**************************************************************

IntegraMed America, Inc. (NASDAQ: INMD), the nation’s leading provider of specialty healthcare services in emerging, technology-focused niches, today announced that The Froedtert and Medical College of Wisconsin Reproductive Medicine Center has begun offering IntegraMed’s Attain(TM) IVF Program - a course of treatment approach that improves patient success with In Vitro Fertilization (IVF).

Mylan Inc. (Nasdaq: MYL) today announced that the company and its subsidiary Mylan Pharmaceuticals Inc. filed a civil lawsuit in the Circuit Court of Monongalia County, W.Va., against the Pittsburgh Post-Gazette, Post-Gazette reporters Len Boselovic and Patricia Sabatini, and others as yet unknown.

Sun Microsystems, Inc. (NASDAQ:JAVA) today announced

...